Valuation: Unicycive Therapeutics, Inc.

Market Cap 133M 116M 109M 99.34M 186M 12.75B 187M 1.31B 506M 6.48B 499M 488M 20.86B P/E 2026 *
-3.88x
P/E 2027 * 2.63x
Enterprise Value 133M 116M 109M 99.34M 186M 12.75B 187M 1.31B 506M 6.48B 499M 488M 20.86B EV / Sales 2026 *
362x
EV / Sales 2027 * 0.88x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * 43.6%
1 day+0.63%
1 week-9.26%
Current month-7.69%
1 month-14.74%
3 months-29.93%
6 months-28.99%
Current year-16.81%
1 week 4.69
Extreme 4.6914
5.35
1 month 4.69
Extreme 4.6914
5.79
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 A Free

Chief Operating Officer

169,500 0.6716%
5/14/26 A Free

Executive/Senior Manager

169,500 0.6716%
5/14/26 A Free

Chief Financial Officer

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%-9.26%+17.36%-29.70% 133M
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+1.82%+38.93%+77.73% 62.32B
-3.21%-7.27%-17.73%+351.98% 27.07B
-2.64%-0.69%-0.26%-11.90% 24.78B
+0.71%+8.50%+27.76%-15.29% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.22%+3.99%+44.28%+173.35% 14.49B
+0.73%+1.71%-7.18%+886.19% 14.14B
-0.54%-0.56%+20.59%+224.93% 12.35B
Average -0.57%+0.50%+34.09%+204.83% 26.23B
Weighted average by Cap. -0.59%+1.38%+35.26%+164.74%

Financials

2026 *2027 *
Net sales 367K 320K 302K 274K 514K 35.18M 516K 3.62M 1.4M 17.89M 1.38M 1.35M 57.56M 150M 131M 124M 112M 210M 14.42B 211M 1.48B 572M 7.33B 564M 552M 23.58B
Net income -34.62M -30.18M -28.5M -25.88M -48.49M -3.32B -48.69M -341M -132M -1.69B -130M -127M -5.43B 56.21M 49.01M 46.28M 42.02M 78.74M 5.39B 79.07M 554M 214M 2.74B 211M 206M 8.82B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
18/09/26 $4.800 +0.63% 1,066,010
17/09/26 $4.770 -0.21% 648,264
16/09/26 $4.780 +1.49% 906,356
15/09/26 $4.710 -8.54% 1,691,133
14/09/26 $5.150 -2.65% 671,002
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.770USD
Average target price
29.60USD
Spread / Average Target
+520.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!